1-7 of 7
Thomas Prébet, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Direct Comparison of High Dose Cytarabine to Combination of Gemtuzumab and High Dose Cytarabine for Acute Myeloid Leukemia Patients in First Relapse Confirmed the Benefit of Gemtuzumab Based Regimens.

Thomas Prébet, MD, Aude Charbonnier, MD, PhD, Anne Etienne, MD, Evelyne D'Incan, MD, Sabine Fürst, MD, Didier Blaise, MD, Norbert Vey, MD
Journal: Blood
Blood (2009) 114 (22): 2051.
https://doi.org/10.1182/blood.V114.22.2051.2051
Published: 2009
Journal Articles

Long Lasting Alteration of Natural Killer Cells Post-Chemotherapy in Elderly Patients with Acute Myeloid Leukemia (AML).

Daniel Olive, MD, PhD, Nicolas Anfossi, Pascale Andre, PhD, Jerome Rey, Florence Orlanducci, Violette Breso, Valentine Peri, Thomas Prébet, MD, Aude Charbonnier, MD, PhD, Eloise Perrot, Francois Romagne, PhD, Norbert Vey
Journal: Blood
Blood (2009) 114 (22): 1653.
https://doi.org/10.1182/blood.V114.22.1653.1653
Published: 2009
Journal Articles

Donor Stem Cell Source Does Not Impact Outcome of High Risk (HR) Acute Myeloblastic Leukaemia (AML) Patients After Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation (RIC-ALLO).

Sabine Furst, MD, Luca Castagna, MD, Thomas Prébet, MD, Claude Lemarie, Jean El Cheikh, MD, Catherine Faucher, MD, Norbert Vey, MD, Aude Charbonnier, MD, PhD, Patrick Ladaique, MD, Christian Chabannon, MD, PhD, Didier Blaise, MD
Journal: Blood
Blood (2009) 114 (22): 4339.
https://doi.org/10.1182/blood.V114.22.4339.4339
Published: 2009
Journal Articles

A Phase I Study of the Anti-Natural Killer Inhibitory Receptor (KIR) Monoclonal Antibody (1-7F9, IPH2101) in Elderly Patients with Acute Myeloid Leukemia (AML): Clinical and Immunological Effects of a Single Dose Followed by Repeated Dosing.

Norbert Vey, Jean-Henri Bourhis, MD, PhD, Herve Dombret, MD, PhD, Dominique Bordessoule, Thomas Prébet, MD, Aude Charbonnier, Stephane de Botton, Nicolas Boissel, MD, PhD, Christine d'Arnoux, MD, Francois Romagne, PhD, Pascale Andre, PhD, Jerome Tiollier, Patrick Squiban, Didier Blaise, Daniel Olive, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 632.
https://doi.org/10.1182/blood.V114.22.632.632
Published: 2009
Journal Articles

A Phase II Study of Post–Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study.

Claude Gardin, MD, Thomas Prébet, MD, Krimo Bouabdallah, MD, Denis Caillot, MD, Agnès Guerci, MD, PhD, Emmanuel Raffoux, MD, Jean Pierre Marolleau, MD, Cecile Pautas, MD, Anne Banos, MD, Chantal Himberlin, MD, Anne-Laure Taksin, MD, Arnaud Pigneux, MD, PhD, Xavier Thomas, MD, PhD, Tony Jernival, Norbert Vey, Francois Dreyfus, MD, PhD, Sylvie Chevret, PhD, Herve Dombret, MD, PhD, Pierre Fenaux
Journal: Blood
Blood (2009) 114 (22): 844.
https://doi.org/10.1182/blood.V114.22.844.844
Published: 2009
Journal Articles

Analysis of NK Cells Receptors and NK Cells Ligands in Acute Myeloid Leukemia: Comparisons Between the Blood and the Bone Marrow.

Jerome Rey, Eloise Perrot, Caroline Veuillen, Thomas Prébet, MD, Anne Etienne, Aude Charbonnier, Evelyne D'Incan, Norbert Vey, Daniel Olive, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1643.
https://doi.org/10.1182/blood.V114.22.1643.1643
Published: 2009
Journal Articles

Tandem Auto-Allo in Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR).

Luca Castagna, Sabine Furst, MD, Thomas Prébet, MD, Jean El Cheikh, Aude Charbonnier, Catherine Faucher, Mohamad Mohty, MD, PhD, Norbert Vey, Didier Blaise
Journal: Blood
Blood (2009) 114 (22): 3355.
https://doi.org/10.1182/blood.V114.22.3355.3355
Published: 2009